GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Cash Flow from Investing

Provention Bio (Provention Bio) Cash Flow from Investing : $-88.13 Mil (TTM As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Provention Bio Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2022, Provention Bio spent $0.37 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $18.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $68.90 Mil for other investing activities. In all, Provention Bio spent $51.27 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2022.


Provention Bio Cash Flow from Investing Historical Data

The historical data trend for Provention Bio's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio Cash Flow from Investing Chart

Provention Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial - -46.25 25.17 -31.10 -88.13

Provention Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.69 9.60 -0.23 -46.23 -51.27

Provention Bio Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Provention Bio's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Provention Bio's Cash Flow from Investing for the quarter that ended in Dec. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provention Bio  (NAS:PRVB) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Provention Bio's purchase of property, plant, equipment for the three months ended in Dec. 2022 was $-0.37 Mil. It means Provention Bio spent $0.37 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Provention Bio's sale of property, plant, equipment for the three months ended in Dec. 2022 was $0.00 Mil. It means Provention Bio gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Provention Bio's purchase of business for the three months ended in Dec. 2022 was $0.00 Mil. It means Provention Bio spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Provention Bio's sale of business for the three months ended in Dec. 2022 was $0.00 Mil. It means Provention Bio gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Provention Bio's purchase of investment for the three months ended in Dec. 2022 was $0.00 Mil. It means Provention Bio spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Provention Bio's sale of investment for the three months ended in Dec. 2022 was $18.00 Mil. It means Provention Bio gained $18.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Provention Bio's net Intangibles purchase and sale for the three months ended in Dec. 2022 was $0.00 Mil. It means Provention Bio paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Provention Bio's cash from discontinued investing activities for the three months ended in Dec. 2022 was 0.00 Mil. It means Provention Bio paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Provention Bio's cash from other investing activities for the three months ended in Dec. 2022 was $-68.90 Mil. It means Provention Bio paid $68.90 Mil for other investing activities.


Provention Bio Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Provention Bio's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Provention Bio (Provention Bio) Business Description

Traded in Other Exchanges
N/A
Address
55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Executives
Sessa Capital (master), L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer director, 10 percent owner, officer: President and CEO PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon director, 10 percent owner, officer: Chief Scientific Officer C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel officer: Chief Accounting Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien officer: Chief People Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi officer: Chief Operations Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio officer: Chief Quality Officer ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos officer: Chief Medical Officer & COO ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche officer: Chief Financial Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701